2023
A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes
Wilson F, Yamamoto Y, Martin M, Coronel-Moreno C, Li F, Cheng C, Aklilu A, Ghazi L, Greenberg J, Latham S, Melchinger H, Mansour S, Moledina D, Parikh C, Partridge C, Testani J, Ugwuowo U. A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes. Nature Communications 2023, 14: 2826. PMID: 37198160, PMCID: PMC10192367, DOI: 10.1038/s41467-023-38532-3.Peer-Reviewed Original ResearchConceptsAcute kidney injuryUsual care groupKidney injuryCare groupAcute Kidney Injury OutcomesAlert groupNon-steroidal anti-inflammatory drugsComposite of progressionHours of randomizationMedications of interestAldosterone system inhibitorsClasses of medicationsProton pump inhibitorsRandomized clinical trialsAnti-inflammatory drugsClinical decision support systemNephrotoxic medicationsHospitalized adultsDiscontinuation ratesCertain medicationsPrimary outcomeSubstantial morbiditySystem inhibitorsPump inhibitorsParallel group
2021
Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19
Menez S, Moledina DG, Thiessen-Philbrook H, Wilson FP, Obeid W, Simonov M, Yamamoto Y, Corona-Villalobos CP, Chang C, Garibaldi BT, Clarke W, Farhadian S, Dela Cruz C, Coca SG, Parikh CR, Investigators T, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19. American Journal Of Kidney Diseases 2021, 79: 257-267.e1. PMID: 34710516, PMCID: PMC8542781, DOI: 10.1053/j.ajkd.2021.09.008.Peer-Reviewed Original ResearchConceptsAdverse kidney outcomesNeutrophil gelatinase-associated lipocalinUrinary biomarkersBiomarker levelsKidney outcomesPrimary outcomeClinical AKIKidney injuryComposite outcomeCOVID-19KDIGO stage 3 AKIKidney injury molecule-1Cox proportional hazards regressionEpidermal growth factor levelsStage 3 AKIPrimary composite outcomeInjury molecule-1Kidney disease progressionGelatinase-associated lipocalinAdditional prognostic informationComposite outcome eventsProportional hazards regressionCOVID-19 patientsGrowth factor levelsCoronavirus disease 2019Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial
Wilson FP, Martin M, Yamamoto Y, Partridge C, Moreira E, Arora T, Biswas A, Feldman H, Garg AX, Greenberg JH, Hinchcliff M, Latham S, Li F, Lin H, Mansour SG, Moledina DG, Palevsky PM, Parikh CR, Simonov M, Testani J, Ugwuowo U. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. The BMJ 2021, 372: m4786. PMID: 33461986, PMCID: PMC8034420, DOI: 10.1136/bmj.m4786.Peer-Reviewed Original ResearchConceptsAcute kidney injuryElectronic health record alertsKidney injuryPrimary outcomeMedical recordsYale New Haven Health SystemCare practicesGlobal Outcomes creatinine criteriaLarge tertiary care centerComposite of progressionDays of randomizationReceipt of dialysisPrespecified secondary outcomesTertiary care centerPatients' medical recordsSmall community hospitalNon-teaching hospitalsElectronic health recordsCreatinine criteriaUsual careSecondary outcomesAdult inpatientsKidney diseaseClinical centersWorse outcomes
2020
A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children
Sandokji I, Yamamoto Y, Biswas A, Arora T, Ugwuowo U, Simonov M, Saran I, Martin M, Testani JM, Mansour S, Moledina DG, Greenberg JH, Wilson FP. A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children. Journal Of The American Society Of Nephrology 2020, 31: 1348-1357. PMID: 32381598, PMCID: PMC7269342, DOI: 10.1681/asn.2019070745.Peer-Reviewed Original ResearchConceptsExternal validation cohortValidation cohortElectronic health recordsSevere AKIClinical risk stratification toolDevelopment of AKIHealth recordsRisk stratification toolInternal validation cohortLength of stayCharacteristic curveElectronic medical recordsNeonatal AKIInpatient mortalitySecondary outcomesHospital admissionPrimary outcomeHospitalized childrenCreatinine valuesMedical recordsStudy populationAKICohortChildrenPredictive variables
2019
Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery
Patel DM, Thiessen-Philbrook H, Brown JR, McArthur E, Moledina DG, Mansour SG, Shlipak MG, Koyner JL, Kavsak P, Whitlock RP, Everett AD, Malenka DJ, Garg AX, Coca SG, Parikh CR. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American Heart Journal 2019, 220: 253-263. PMID: 31911262, PMCID: PMC7008086, DOI: 10.1016/j.ahj.2019.11.014.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersBlood ProteinsCardiac Surgical ProceduresCardiovascular DiseasesCause of DeathCohort StudiesCoronary Artery BypassFemaleGalectin 3GalectinsHeart Valve Prosthesis ImplantationHumansInterleukin-1 Receptor-Like 1 ProteinMalePostoperative ComplicationsProspective StudiesVentricular RemodelingConceptsGal-3 levelsCardiovascular eventsCardiac surgerySignificant post-operative morbidityGalectin-3Gal-3 valuesPlasma soluble ST2Composite primary outcomePrimary composite outcomePost-operative morbidityCongestive heart failurePost-operative changesPotential clinical utilityRandom-effects modelPlasma sST2Soluble suppressionComposite outcomeHazard ratioProspective cohortTumorigenicity 2Heart failurePrimary outcomeMyocardial remodelingClinical covariatesClinical utility